medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2022, Number 2

<< Back

Rev Mex Urol 2022; 82 (2)

Unusual cause of obstructive uropathy: a pelvic chondrosarcoma

Corona-Montes VE, Fernández-Noyola G, Chablé-Montero F, Cervantes-Sánchez AM, Cruz-Reyes C, Borja-Menéndez DA, Rosas-Nava JE, Sánchez-Núñez JE

Language: Spanish
References: 16
Page:
PDF size: 186.14 Kb.


ABSTRACT

We report the case of a 37-year-old male patient who presented renal failure secondary to a pelvic tumor. The diagnostic approach revealed a pubic-dependent tumor corresponding to a mesenchymal chondrosarcoma that conditioned obstructive uropathy as well as bladder and sigmoid compression. Mesenchymal chondrosarcomas are soft tissue dependent sarcomas with an extremely rare incidence, the clinical importance of our report is due to the fact that chondrosarcomas, must be considered in the differential diagnoses of obstructive uropathy due to their compressive effect on the urinary tract. We carry out a brief review of diagnostic approach, therapeutic options and prognosis of this pathology.


REFERENCES

  1. Lichtenstein L, Bernstein D. Unusual benignand malignant chondroid tumors of bone. Asurvey of some mesenchymal cartilage tumorsand malignant chondroblastic tumors, includinga few multicentric ones, as well as many atypicalbenign chondroblastomas and chondromyxoidfibromas. Cancer. 1959;12(6):1142–57.doi: https://doi.org/10.1002/1097-0 1 4 2 (195911/12) 12: 6 < 1142:: AID-CNCR2820120610>3.0.CO;2-D

  2. Lin O,, Zakowski MF. Cytology of SoftTissue, Bone, and Skin. In: ComprehensiveCytopathology. 3rd ed. Elsevier; 2008. p.Philadelphia.

  3. Ghafoor S, Hameed MR, Tap WD, HwangS. Mesenchymal chondrosarcoma: imagingfeatures and clinical findings. SkeletalRadiol. 2021;50(2):333–41. doi: https://doi.org/10.1007/s00256-020-03558-x

  4. Casali PG, Abecassis N, Bauer S, Biagini R,Bielack S, Bonvalot S, et al. Soft tissue andvisceral sarcomas: ESMO–EURACAN ClinicalPractice Guidelines for diagnosis, treatment andfollow-up†. Annals of Oncology. 2018;29:iv51–67. doi: https://doi.org/10.1093/annonc/mdy096

  5. Wein AJ, M.D AWP, M.D LRK, Novick AC.Campbell-Walsh Urologia/ Campbell-WalshUrology. 11th ed. Ed. Médica Panamericana;2008. 808 p.

  6. Xu J, Li D, Xie L, Tang S, Guo W. MesenchymalChondrosarcoma of Bone and Soft Tissue: ASystematic Review of 107 Patients in the Past 20Years. PLOS ONE. 2015 Apr 7;10(4):e0122216.doi: https://doi.org/10.1371/journal.pone.0122216

  7. Frezza AM, Cesari M, Baumhoer D, Biau D,Bielack S, Campanacci DA, et al. Mesenchymalchondrosarcoma: prognostic factors andoutcome in 113 patients. A EuropeanMusculoskeletal Oncology Society study. Eur JCancer. 2015;51(3):374–81. doi: https://doi.org/10.1016/j.ejca.2014.11.007

  8. Tsavaris O, Economopoulou P, Kotsantis I,Reppas L, Avgerinou C, Spathas N, et al. ClinicalBenefit of Pazopanib in a Patient with MetastaticChondrosarcoma: A Case Report and Review ofthe Literature. Frontiers in Oncology. 2018;8.doi: https://doi.org/10.3389/fonc.2018.00045

  9. Nakashima Y, Unni KK, Shives TC, Swee RG,Dahlin DC. Mesenchymal chondrosarcomaof bone and soft tissue. A review of 111cases. Cancer. 1986;57(12):2444–53.doi: https://doi.org/10.1002/1097-0142 (19860615) 57: 12 < 2444 :: AIDCNCR2820571233>3.0.CO;2-K

  10. Wang L, Motoi T, Khanin R, Olshen A, MertensF, Bridge J, et al. Identification of a novel,recurrent HEY1-NCOA2 fusion in mesenchymalchondrosarcoma based on a genome-widescreen of exon-level expression data. Genes,Chromosomes and Cancer. 2012;51(2):127–39.doi: https://doi.org/10.1002/gcc.20937

  11. Shapeero LG, Vanel D, Couanet D, ContessoG, Ackerman LV. Extraskeletal mesenchymalchondrosarcoma. Radiology. 1993;186(3):819–26. doi: https://doi.org/10.1148/radiology.186.3.8430193

  12. Mendenhall WM, Reith JD, ScarboroughMT, Stechmiller BK, Mendenhall NP.Mesenchymal Chondrosarcoma. Int J PartTher. 2016;3(2):300–4. doi: https://doi.org/10.14338/IJPT-16-00019.1

  13. Tansir G, Rastogi S, Barwad A, Dhamija E. Longlasting response with trabectedin monotherapyin relapsed metastatic mesenchymalchondrosarcoma. Clinical Sarcoma Research.2020;10(1):16. doi: https://doi.org/10.1186/s13569-020-00138-4

  14. Kawai A, Araki N, Sugiura H, Ueda T,Yonemoto T, Takahashi M, et al. Trabectedinmonotherapy after standard chemotherapyversus best supportive care in patients withadvanced, translocation-related sarcoma: arandomised, open-label, phase 2 study. LancetOncol. 2015;16(4):406–16. doi: https://doi.org/10.1016/S1470-2045(15)70098-7

  15. Araki N, Takahashi S, Sugiura H, Ueda T,Yonemoto T, Takahashi M, et al. Retrospectiveinter- and intra-patient evaluation of trabectedinafter best supportive care for patients withadvanced translocation-related sarcoma afterfailure of standard chemotherapy. EuropeanJournal of Cancer. 2016;56:122–30. doi: https://doi.org/10.1016/j.ejca.2015.12.014

  16. Cesari M, Bertoni F, Bacchini P, Mercuri M,Palmerini E, Ferrari S. Mesenchymal chondrosarcoma.An analysis of patients treated at asingle institution. Tumori. 2007;93(5):423–7.




2020     |     www.medigraphic.com